TG Therapeutics, Inc. (TGTX)

Market Cap	9.04B +88.0%
Revenue (ttm)	897.76M +68.8%
Net Income	106.06M -76.3%
EPS	0.66 -76.2%
Shares Out	140.10M
PE Ratio	97.76
Forward PE	24.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,579,114
Open	65.76
Previous Close	65.76
Day's Range	63.28 - 65.86
52-Week Range	26.76 - 68.03
Beta	1.81
Analysts	Buy
Price Target	77.50 (+20.04%)
Earnings Date	Nov 9, 2026

About TGTX

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 14, 1995
• Employees: 399
• Stock Exchange: Nasdaq
• Ticker Symbol: TGTX
• Website: https://www.tgtherapeutics.com

Financial Performance

In 2025, TG Therapeutics's revenue was $616.29 million, an increase of 87.32% compared to the previous year's $329.00 million. Earnings were $447.18 million, an increase of 1812.41%.

Analyst Summary

According to 7 analysts, the average rating for TGTX stock is "Buy." The 12-month stock price target is $77.5, which is an increase of 20.04% from the latest price.

Price Target

$77.5

(20.04% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 13, 2026

Data Sources Report a data error